Effects of calcitriol on bone mineral density in patients treated with esomeprazole

Autor:	Chuan Cen, Lingfei Wu, Haiyong Zhang, Xin Ding, Congwu Huang
Rok vydání:	2014
Předmět:	Adult Male medicine.medical_specialty Peptic Ulcer Calcitriol medicine.drug_class Pharmaceutical Science Proton-pump inhibitor chemistry.chemical_element Calcium Gastroenterology Esomeprazole Bone Density Internal medicine Drug Discovery medicine Humans Pharmacology Bone mineral Bone Density Conservation Agents Proton Pump Inhibitors General Medicine Middle Aged Endocrinology Treatment Outcome Complementary and alternative medicine chemistry Molecular Medicine Alkaline phosphatase Drug Therapy Combination Female Hemoglobin Glucocorticoid medicine.drug
Zdroj:	Pharmaceutical biology. 52(10)
ISSN:	1744-5116
Popis:	Proton pump inhibitor (PPI) increases the risk of decrease in bone mineral density (BMD). However, whether calcitrol improves this situation is unknown.The current study investigates the effects of calcitriol on BMD in patients with esomeprazole therapy.Three hundred and eighty-six participants with gastrointestinal ulcerations were enrolled and randomly assigned into controlled and supplemented groups. Participants in the controlled group were prescribed esomeprazole (20 mg/qd), while the supplemented group was prescribed esomeprazole (20 mg/qd) and calcitriol (2.5 μg/qd). BMD, serum levels of calcium, carboxy-terminal collagen crosslinks (CTX), and alkaline-phosphatase (ALP) were assessed.(1) No significant between-group difference of age, gender, smoking, previous glucocorticoid use and hemoglobin level was found; (2) after 10.6 ± 0.8 d of PPI therapy, BMD T score in the controlled group was slightly increased compared with initial (-1.25 ± 0.08 versus -1.28 ± 0.06, p = 0.084), while there was no change in the supplemented group (-1.25 ± 0.05 versus -1.26 ± 0.03, p = 0.308); (3) during study termination, calcium level in the supplemented group was slightly higher than the controlled group (2.05 ± 0.03 mmol/L versus 2.01 ± 0.05 mmol/L, p = 0.073), while no significant differences of CTX (366.57 ± 43.71 pg/mL versus 373.15 ± 50.23 pg/mL, p = 0.036) and ALP were found among these two groups (50.47 ± 9.32 U/L versus 52.23 ± 10.45 U/L, p = 0.075).Patients with gastrointestinal ulcerations with esomeprazole therapy, calcitriol supplement showed no efficacy on BMD changes.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7045f95c8b8500bfdcdd4637c7202913 https://pubmed.ncbi.nlm.nih.gov/25046547 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.